Publication | Closed Access

Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy

Cell-free DnaMedicineColorectal CancerPathologyCancer GenomicsEgfr MutationsCancer GeneticsMolecular DiagnosticsOncologyCell BiologyTumor BiologySecondary Resistance